NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027

 NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its hearing before the Nasdaq Hearings Panel (the "Panel") is scheduled for November 10, 2026, following its timely appeal of the October 1, 2026 Staff Delisting Determination.

 

The appeal stays the suspension and delisting action, and NeuroSense's ordinary shares and warrants are expected to continue trading on The Nasdaq Capital Market under "NRSN" and "NRSNW," respectively, pending the Panel's decision.

Plan to Regain Nasdaq Compliance

NeuroSense has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The only remaining deficiency identified in the October 1 Staff Determination is the $35 million minimum market value of listed securities requirement under Rule 5550(b)(2).

At the hearing, the Company intends to present its plan to meet that requirement or the alternative $2.5 million stockholders' equity standard under Rule 5550(b)(1), including proposed measures to strengthen its balance sheet and stockholders' equity, together with implementation timelines.

NeuroSense intends to request an exception period to execute its plan. The Panel may grant an exception of up to 180 days from the October 1 Staff Determination, but there is no assurance that an exception will be granted or that the Company will regain and maintain compliance.

Upcoming PrimeC Milestones

Health Canada New Drug Submission for PrimeC in ALS: targeted for December 2026.
Decision on non-dilutive grant funding for Phase 3 PARAGON: expected in Q1 2027, subject to completion of the ongoing grant review.